← Back to Search

PD-1 Inhibitor

Q702 + Pembrolizumab for Advanced Solid Cancers

Phase 1 & 2

Recruiting

Research Sponsored by Qurient Co., Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have measurable disease per RECIST v 1.1. as assessed by local site investigator/radiology

Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Timeline

Screening 3 weeks

Treatment Varies

Follow Up cycle 1 day 1 and day 22 (each cycle is 42 days)

Awards & highlights

Study Summary

This trialis testing a new combination of drugs to treat advanced cancers of the esophagus, stomach, liver, and cervix.

Who is the study for?

This trial is for adults with advanced esophageal, gastric/GEJ, hepatocellular, or cervical cancers that worsened after anti-PD1/PD-L1 therapy. Participants must be able to consent, have measurable disease per RECIST v1.1., an ECOG status of 0 or 1, and a life expectancy over 3 months. Pregnant or breastfeeding women and those on certain drugs are excluded.Check my eligibility

What is being tested?

The study tests the safety and early effectiveness of Q702 combined with pembrolizumab in selected cancer patients. It's an open-label phase 1B/2 trial where all participants receive the experimental drug combination to see how well it works.See study design

What are the potential side effects?

Potential side effects may include typical reactions from immunotherapy like fatigue, skin reactions, inflammation-related symptoms across various organs (e.g., colitis), as well as issues specific to tyrosine kinase inhibitors such as hypertension and diarrhea.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer can be measured using standard imaging tests.

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

Select...

My cancer has worsened despite treatment with specific immune therapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ cycle 1 day 1 and day 22 (each cycle is 42 days)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~cycle 1 day 1 and day 22 (each cycle is 42 days)

This trial's timeline: 3 weeks for screening, Varies for treatment, and cycle 1 day 1 and day 22 (each cycle is 42 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Therapeutic procedure

Tumor response using RECIST version 1.1 throughout study

Secondary outcome measures

Change in the area under curve (AUC) of Q702 and its primary metabolites

Trial Design

2Treatment groups

Experimental Treatment

Group I: Dose expansion of Q702 in combination with fixed dose of pembrolizumabExperimental Treatment2 Interventions

Give intravenously once every three week at 200 mg

Group II: Dose escalation of Q702 in combination with fixed dose of pembrolizumabExperimental Treatment2 Interventions

Give one week on/one week off at selected dose level

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

FDA approved

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Qurient Co., Ltd.Lead Sponsor

8 Previous Clinical Trials

687 Total Patients Enrolled

Merck Sharp & Dohme LLCIndustry Sponsor

3,888 Previous Clinical Trials

5,054,937 Total Patients Enrolled

Media Library

Pembrolizumab (PD-1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05438420 — Phase 1 & 2

Cervical Cancer Research Study Groups: Dose escalation of Q702 in combination with fixed dose of pembrolizumab, Dose expansion of Q702 in combination with fixed dose of pembrolizumab

Cervical Cancer Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT05438420 — Phase 1 & 2

Pembrolizumab (PD-1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05438420 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still an opportunity for individuals to partake in this research?

"According to information found on clinicaltrials.gov, recruitment for this particular trial has ceased. It was initially posted in December of 2023 and modified one month later; however, there are currently 1441 other trials with active participant enrollment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

2023. "Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05438420.